Digital therapeutics are transitioning from curiosities to valuable additions to the pharmaceutical armamentarium, but they’re still not common in mainstream medicine.

These novel therapeutics aren’t necessarily designed for drug replacement. Instead, digital therapeutics are said to “wrap-around the pill” as “pill+” strategies to treat the symptoms the drug doesn’t manage.

“We’re entering an exciting phase of the field,” James R. Williams, Ph.D., head of external innovation and alliances at Biogen Digital Health, told BioSpace. “A lot of the initial digital therapy entrants targeted cognitive behavioral therapies and made them more broadly available during COVID. Now we’re now seeing other innovators entering, asking what more can be done. There are a lot of opportunities.”

Follow us:

Share this article:

LinkedIn
Twitter
Facebook